Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

a family history of cancer, or advanced age (older than 60 years) have an increased risk of developing a neuroendocrine tumor. 7 The prognosis and survival rates for GI neuroendocrine tumors ...

A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...

1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. 2Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, ...

Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

A doctor has issued a warning about a common cancer symptom that often gets "overlooked" by a lot of people. He said it's ...

A doctor has warned that there is one sign of cancer that people often overlook, but it's important to be aware of it, as it ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Trump's freeze on federal grants and loans could total trillions of dollars and cause disruptions in health care research, ...